Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn

[cafead]

via Ionis and its RNAi drug Tegsedi got a head start with England's NHS, putting the pressure on Alnylam's rival med Onpattro. But now, the country's drug cost watchdog has changed its mind and backed the Alnylam drug, too.

article source